Human Trials Of mRNA, India's Vaccine Against Omicron To Begin In February
Human trials of mRNA vaccine against COVID-19's new variant Omicron is to begin from February. Notably, Pune-based Gennova Biopharmaceutical made mRNA vaccine and completed phase I and II trials and submitted a report to the Drugs Controller General of India (DCGI). Along with it, the company also submitted a data of Phase III trials and are waiting for their approval from the Vaccine Subject Expert Committee (SEC).
Tags: mRNA, Omicron Vaccine, Gennova biopharmaceutical, Covid-19, DCGI
Courtesy: The Times Of India